From Disease Silos to Integrated Cardiometabolic Care: Diabetes, Vascular Disease, and Heart Failure
Journal of Diabetes, Volume 18, Issue 9, September 2026.
Zachary T. Bloomgarden +1 more
wiley +1 more source
Real-world effectiveness and cardiovascular outcomes of PCSK9 inhibitor therapy: a prospective registry study. [PDF]
Kafol J +12 more
europepmc +1 more source
PCSK9 Inhibitor Alirocumab Improves Diabetic Cardiomyopathy Through the ERK/p38 MAPK Signaling Pathway. [PDF]
Lin S, Wu B, Sun S, Sun T.
europepmc +1 more source
Identification and evaluation of a lipid-lowering small compound as a PCSK9 inhibitor. [PDF]
Xu R +17 more
europepmc +1 more source
Potential bias in observational PCSK9 inhibitor study. [PDF]
Blais JE, Wong AYS.
europepmc +1 more source
Sociodemographic Characteristics Associated with PCSK9 Inhibitor Use in Individuals with Possible Familial Hypercholesterolemia in Alberta: A Cohort Study. [PDF]
Fineblit SE, Vickers DM, Campbell DJT.
europepmc +1 more source
Impact of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor on Immune-Inflammatory Responses in the Acute Phase of Ischemic Stroke. [PDF]
Li Z +14 more
europepmc +1 more source
Association of PCSK9 Inhibitor Initiation on Statin Adherence and Discontinuation. [PDF]
LaFratte C +5 more
europepmc +1 more source
Determinants of circulating PCSK9 levels and the efficacy of PCSK9 inhibitor therapies in chronic kidney disease: a systematic review. [PDF]
Ábel T, Benczúr B, Csajbókné ÉC.
europepmc +1 more source

